Fenretinide for Dry AMD

Data from a phase 2 trial of fenretinide showed a reduction in the incidence of wet age-related macular degeneration in patients with geographic atrophy, the advanced form of dry age-related macular degeneration.  Alexander M. Eaton, MD, an investigator in the trial, said, “We are hopeful that the complete analysis will further validate these findings as fenretinide could slow vision loss in the millions of Americans who face blindness because of this disease.” The drug reduces VEGF, the proteins that cause growth of leaky vessels in the retina. Fenretinide also regulates complement factor H, which inhibits the inflammatory pathway.

SEE FULL STORY